PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice
使用 Cereblon 敲入小鼠的同基因癌症模型中的 PROTAC 靶向 Tip60
基本信息
- 批准号:10654675
- 负责人:
- 金额:$ 38.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AcetylationAcetyltransferaseAffectAmino AcidsAndrogen ReceptorApoptosisAutoimmunityBindingBirthC57BL/6 MouseCancer ModelCause of DeathCell SeparationCell SurvivalCellsCessation of lifeChemotherapy and/or radiationCisplatinClinical TrialsComplexDNA BindingDNA DamageDNA RepairDataDevelopmentDimerizationEnzymesEventFOXP3 geneGenesGenomic InstabilityGrowthHTATIP geneHistonesHumanImmuneImmunityImmunocompetentImmunodeficient MouseImmunotherapyImpairmentIn VitroIndividualInvestigationIonizing radiationKnock-inKnock-in MouseLeadLung NeoplasmsLysineMalignant NeoplasmsMalignant neoplasm of lungModelingMolecularMusOrganPatientsPopulationProtacProteinsRadiationRadiation therapyRegulatory T-LymphocyteResistanceRoleT cell responseT-LymphocyteTP53 geneTestingTherapeuticTreatment EfficacyTumor EscapeVaccinationWorkXenograft procedureanti-tumor immune responseantitumor effectcancer cellcancer initiationcancer typecastration resistant prostate cancercheckpoint therapychemotherapyclinical developmentconventional therapyeffector T cellimmune checkpoint blockadeimmunoregulationin vivoinhibitorirradiationlung cancer cellmouse modelneoplastic cellnovel therapeuticsphase 1 studypreservationpreventprotein degradationrecruitresponsescreeningtherapeutic targettherapy resistanttooltreatment responsetumortumor growthtumor microenvironmentubiquitin ligaseubiquitin-protein ligase
项目摘要
Project Summary
We will investigate whether therapeutic targeting of Tip60, a histone/protein acetyltransferase essential for the
functions and survival of Foxp3+ T-regulatory (Treg) can significantly decrease Treg functions in vivo while
preserving conventional T cell responses, leading to inhibition of lung tumor growth in murine models. We will
also assess the effects of Tip60 targeting on the DNA damage response within tumors induced by conventional
therapies for lung cancer, including irradiation and cisplatin therapy. We have developed Tip60 PROTAC
(proteolysis targeting chimeric) molecules that recruit the Cereblon E3 ligase so as to promote Tip60
degradation, and we employ Cereblon knock-in (CrbnI391V) immunocompetent C57BL/6 mice in compound
screening and tumor models to facilitate identification of compounds for subsequent clinical development.
Aim 1 - Can Tip60i limit growth of tumors in immunocompetent hosts by decreasing Foxp3+
Treg suppressive function? We have developed several Tip60i, including Crbn- and VHL-based PROTAC
compounds. We will test if Tip60i PROTAC compounds can modulate Treg function and control growth of
experimental lung cancers by (1.1) optimizing Tip60i PROTAC compounds, and testing them (1.2) alone, or in
conjunction with (1.3) vaccination or (1.4) checkpoint inhibitor therapy in CrbnI391V mice. We will also assess
effects of Tip60i on 1.5) normal human Treg and/or Teff cells, and 1.6) human lung cancer associated Treg
cells.
Aim 2 – Determine if Tip60i disrupts DDR actions essential for tumor cell survival. Our
molecular investigations will explore Tip60-dependent mechanisms that promote cellular resistance to genome
instability and normal programmed mechanisms of death, and which underpin cancer initiation and
chemotherapeutic resistance crucial for lung cancer cell survival. We will test if Tip60i compounds have direct
anti-tumor effects by disrupting 2.1) Tip60-dependent p53 activation and/or 2.2) DNA repair mechanisms.
Our studies will facilitate the development of new strategies for immunotherapy in patients with malignancies,
given that the new Tip60-directed therapies have dual mechanisms of action, involving targeting Foxp3+ Treg
cells and intrinsic tumor cell responses to therapy. The data to be generated will likely lead to clinical trials in
patients with lung cancers, and should also have relevance to additional individuals, given the increasingly
recognized potential for immunotherapy in the management of many other types of cancers.
项目摘要
我们将研究Tip 60的治疗靶向是否是一种组蛋白/蛋白乙酰转移酶,
Foxp 3+调节性T细胞(Treg)的功能和存活可显著降低体内Treg功能,
保留常规的T细胞应答,导致在鼠模型中抑制肺肿瘤生长。我们将
还评估了Tip 60靶向对肿瘤内由常规药物诱导的DNA损伤反应的影响。
肺癌的治疗,包括放疗和顺铂治疗。我们开发了Tip 60 PROTAC
(蛋白水解靶向嵌合)分子,其募集Cereblon E3连接酶以促进Tip 60
我们使用Cereblon敲入(CrbnI 391 V)免疫活性C57 BL/6小鼠,
筛选和肿瘤模型,以促进化合物的鉴定,用于随后的临床开发。
目的1 -Tip 60 i能否通过减少Foxp 3+来限制免疫活性宿主中的肿瘤生长
Treg抑制功能?我们已经开发了几种Tip 60 i,包括基于Crbn和VHL的PROTAC
化合物.我们将测试Tip 60 i PROTAC化合物是否可以调节Treg功能并控制肿瘤细胞的生长。
通过(1.1)优化Tip 60 i PROTAC化合物,并单独测试它们(1.2),或
在CrbnI 391 V小鼠中与(1.3)疫苗接种或(1.4)检查点抑制剂疗法联合。我们亦会评估
Tip 60 i对1.5)正常人Treg和/或Teff细胞,和1.6)人肺癌相关Treg的作用
细胞
目的2 -确定Tip 60 i是否破坏肿瘤细胞存活所必需的DDR作用。我们
分子研究将探索Tip 60依赖的机制,促进细胞对基因组的抗性,
不稳定性和正常的程序性死亡机制,这是癌症发生的基础,
化疗耐药性对肺癌细胞存活至关重要。我们将测试Tip 60 i化合物是否具有直接
通过破坏2.1)Tip 60依赖性p53活化和/或2.2)DNA修复机制来产生抗肿瘤作用。
我们的研究将促进恶性肿瘤患者免疫治疗新策略的发展,
鉴于新的Tip 60导向疗法具有双重作用机制,涉及靶向Foxp 3 + Treg,
细胞和内在肿瘤细胞对治疗的反应。所产生的数据可能会导致临床试验,
肺癌患者,并且还应该与其他个体相关,因为越来越多的
免疫疗法在许多其他类型癌症的治疗中具有公认的潜力。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Nuclear Coregulatory Complexes in Tregs as Targets to Promote Anticancer Immune Responses.
- DOI:10.3389/fimmu.2022.909816
- 发表时间:2022
- 期刊:
- 影响因子:7.3
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Wayne William Hancock其他文献
Wayne William Hancock的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Wayne William Hancock', 18)}}的其他基金
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice
使用 Cereblon 敲入小鼠的同基因癌症模型中的 PROTAC 靶向 Tip60
- 批准号:
10163146 - 财政年份:2020
- 资助金额:
$ 38.81万 - 项目类别:
Pre-Transplant Monocyte HDAC6 Expression and Risk of Primary Graft Dysfunction in Clinical Lung Transplant Recipients
临床肺移植受者移植前单核细胞 HDAC6 表达和原发性移植物功能障碍的风险
- 批准号:
10152233 - 财政年份:2020
- 资助金额:
$ 38.81万 - 项目类别:
PROTAC Targeting of Tip60 in Syngeneic Cancer Models Using Cereblon Knock-in Mice
使用 Cereblon 敲入小鼠的同基因癌症模型中的 PROTAC 靶向 Tip60
- 批准号:
10054519 - 财政年份:2020
- 资助金额:
$ 38.81万 - 项目类别:
Pre-Transplant Monocyte HDAC6 Expression and Risk of Primary Graft Dysfunction in Clinical Lung Transplant Recipients
临床肺移植受者移植前单核细胞 HDAC6 表达和原发性移植物功能障碍的风险
- 批准号:
10527372 - 财政年份:2020
- 资助金额:
$ 38.81万 - 项目类别:
Pre-Transplant Monocyte HDAC6 Expression and Risk of Primary Graft Dysfunction in Clinical Lung Transplant Recipients
临床肺移植受者移植前单核细胞 HDAC6 表达和原发性移植物功能障碍的风险
- 批准号:
10318217 - 财政年份:2020
- 资助金额:
$ 38.81万 - 项目类别:
Class IIa HDAC and MEF2 Targeting to Promote Foxp3+ Treg Cell Functions
IIa 类 HDAC 和 MEF2 靶向促进 Foxp3 Treg 细胞功能
- 批准号:
9079672 - 财政年份:2016
- 资助金额:
$ 38.81万 - 项目类别:
INHIBITION OF A TREG DEUBIQUITINASE, USP7, PROMOTES ANTI-TUMOR IMMUNITY
抑制 TREG 去泛素酶 (USP7) 可促进抗肿瘤免疫
- 批准号:
8884257 - 财政年份:2015
- 资助金额:
$ 38.81万 - 项目类别:
Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients
Foxp3 Treg 细胞
- 批准号:
8338293 - 财政年份:2012
- 资助金额:
$ 38.81万 - 项目类别:
Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients
Foxp3 Treg 细胞
- 批准号:
8676591 - 财政年份:2012
- 资助金额:
$ 38.81万 - 项目类别:
Foxp3+ Treg Cells & Primary Graft Dysfunction in Clinical Lung Tx Recipients
Foxp3 Treg 细胞
- 批准号:
8469907 - 财政年份:2012
- 资助金额:
$ 38.81万 - 项目类别:
相似海外基金
Dissecting out differential molecular phenotypes across Lysine(K) AcetylTransferase mutations in mouse development
剖析小鼠发育过程中赖氨酸(K)乙酰转移酶突变的差异分子表型
- 批准号:
10727966 - 财政年份:2023
- 资助金额:
$ 38.81万 - 项目类别:
Targeting lysine acetyltransferase MOF/KAT8 in lung cancer
靶向赖氨酸乙酰转移酶 MOF/KAT8 在肺癌中的作用
- 批准号:
10601761 - 财政年份:2023
- 资助金额:
$ 38.81万 - 项目类别:
Roles of lysine acetyltransferase 6 complexes in cerebral development and neurodevelopmental disorders
赖氨酸乙酰转移酶 6 复合物在大脑发育和神经发育障碍中的作用
- 批准号:
479754 - 财政年份:2023
- 资助金额:
$ 38.81万 - 项目类别:
Operating Grants
Defining the cell-type specific role of histone acetyltransferase KAT2a in nucleus accumbens D1 medium spiny neurons as a driver of cocaine use disorder
定义组蛋白乙酰转移酶 KAT2a 在伏隔核 D1 中型多棘神经元中作为可卡因使用障碍驱动因素的细胞类型特异性作用
- 批准号:
10679238 - 财政年份:2023
- 资助金额:
$ 38.81万 - 项目类别:
Examination of the Histone Acetyltransferase CBP in the Remodelling of Thermogenic Adipose Tissues
组蛋白乙酰转移酶 CBP 在生热脂肪组织重塑中的检测
- 批准号:
486467 - 财政年份:2022
- 资助金额:
$ 38.81万 - 项目类别:
Studentship Programs
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
开发用于癌基因驱动癌症的 p300/CBP 组蛋白乙酰转移酶抑制剂
- 批准号:
10344246 - 财政年份:2022
- 资助金额:
$ 38.81万 - 项目类别:
Nuclear activity of carnitine acetyltransferase
肉毒碱乙酰转移酶的核活性
- 批准号:
RGPIN-2018-06089 - 财政年份:2022
- 资助金额:
$ 38.81万 - 项目类别:
Discovery Grants Program - Individual
Development of p300/CBP histone acetyltransferase inhibitors for oncogene-driven cancers
开发用于癌基因驱动癌症的 p300/CBP 组蛋白乙酰转移酶抑制剂
- 批准号:
10627744 - 财政年份:2022
- 资助金额:
$ 38.81万 - 项目类别:
Characterizing the role of the NuA3 histone acetyltransferase complex during transcription
表征 NuA3 组蛋白乙酰转移酶复合物在转录过程中的作用
- 批准号:
557615-2021 - 财政年份:2022
- 资助金额:
$ 38.81万 - 项目类别:
Postdoctoral Fellowships
Structural and functional studies of histone acetyltransferase complexes
组蛋白乙酰转移酶复合物的结构和功能研究
- 批准号:
RGPIN-2018-03951 - 财政年份:2022
- 资助金额:
$ 38.81万 - 项目类别:
Discovery Grants Program - Individual